SkinnyRx vs Hims & Hers: An Honest Head-to-Head GLP-1 Telehealth Review

Why this comparison exists in 2026

If you have searched "GLP-1 telehealth" anytime in the last twelve months, you have almost certainly seen ads from both SkinnyRx and Hims & Hers. They dominate paid acquisition in the weight-loss space, they target overlapping audiences, and yet they are fundamentally different products. Treating them as interchangeable — "just another telehealth GLP-1" — leads to the wrong choice for a lot of people.

The 2026 telehealth landscape pushed these two brands further apart, not closer:

• The FDA enforcement wave (March 2026) reshaped the compounded GLP-1 space. Approximately 30 telehealth companies received warning letters about promotional claims. SkinnyRx was among them and revised its language. Hims, operating mostly in the FDA-approved branded path, was not part of that letter wave.
• The Wegovy oral pill launch (January 5, 2026) gave Hims a new FDA-approved pill option starting at $149/month for lower doses, reaching $299/month at the highest dose — narrowing some of the price gap to compounded.
• Compounded prices fell roughly 30-50% across 2025-2026 as competition intensified. SkinnyRx held a $199 price point that looked aggressive in 2024 and now looks more typical of the legitimate compounded tier.

The result: SkinnyRx and Hims now serve clearly distinct readers. The point of this article is to help you figure out which one of those readers is you.

The two products in one paragraph each

SkinnyRx in plain English

SkinnyRx is a U.S. telehealth company that connects patients with licensed prescribers and a 503A compounding pharmacy partner (operated by Lean Rx, Inc. out of Sacramento, CA). After a brief intake, eligible patients receive compounded semaglutide for $199/month, available in injectable, sublingual, or oral tablet formulations. The pricing includes provider consultation, prescription, and shipping. Affirm financing is integrated at checkout. SkinnyRx received an FDA warning letter in early 2026 regarding promotional claims (not a product safety issue) and has continued operating after revising the flagged marketing language.

Hims & Hers in plain English

Hims & Hers Health, Inc. (NYSE: HIMS) is a publicly traded direct-to-consumer telehealth company with multiple verticals (weight loss, dermatology, mental health, sexual health, hair). Their GLP-1 program is positioned around FDA-approved branded medications: Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly). Pricing runs $299-499/month depending on the program tier, dose, and whether the user qualifies for the Wegovy oral pill at $149-299/month. The infrastructure is large, the support is 24/7, and the pricing is transparent — but it is materially more expensive than compounded alternatives.

Side-by-side specs

Pricing accurate as of May 2026. Verify directly with each provider — telehealth pricing is fluid.

Mechanism: same molecule family, different regulatory status

The product behind both providers comes from the same GLP-1 receptor agonist drug class. What differs is whether you are getting a compounded version or the FDA-approved finished product.

SkinnyRx: compounded semaglutide via 503A pharmacy

SkinnyRx delivers semaglutide compounded by a state-licensed 503A pharmacy under the FDA Modernization Act of 1997. The active ingredient — semaglutide — is the same molecule used in FDA-approved Ozempic and Wegovy. The STEP 1 trial^[1] demonstrated 14.9% mean body weight loss over 68 weeks at the 2.4 mg dose, which is the dose target compounded telehealth providers titrate users toward.

What "compounded" actually means: a 503A pharmacy is allowed to prepare custom medication for an individual patient with a valid prescription. The active ingredient is the same; the FDA does not, however, review and approve each batch of compounded medication for potency, purity, and stability the way it does for Novo Nordisk's branded Wegovy. This creates a quality variance that is real but manageable when the pharmacy is reputable and licensed.

SkinnyRx discloses its pharmacy partner (Lean Rx, Inc.). That transparency is meaningful — sketchier providers refuse to name the pharmacy, which makes it impossible to verify licensure or request a Certificate of Analysis.

Hims & Hers: FDA-approved branded medications

Hims's flagship GLP-1 offering is FDA-approved Wegovy (semaglutide) and Zepbound (tirzepatide). These are the same products you would receive at a major chain pharmacy with a prescription from your primary care doctor — Novo Nordisk and Eli Lilly manufacture them, the FDA reviews each batch, and the entire regulatory chain is fully established.

Tirzepatide via Zepbound is a dual GLP-1 + GIP agonist. Its pivotal SURMOUNT-1 trial^[2] demonstrated 22.5% mean body weight loss at the 15 mg weekly dose — meaningfully higher than semaglutide alone. Users who specifically want tirzepatide (which SkinnyRx does not currently offer in compounded form through this comparison) and want it FDA-approved have to go through a Hims-style pathway.

The maintenance side: SURMOUNT-4^[3] demonstrated that continuing tirzepatide preserves weight loss, while withdrawing causes substantial regain — a chronic-disease framing that argues for picking a provider you can stay with for years, not months.

Pricing deep-dive: where the gap actually comes from

The math of $199 vs $299-499

Annualized, the price gap is significant:

• SkinnyRx at $199/month: $2,388/year
• Hims entry tier at $299/month: $3,588/year (a $1,200 premium)
• Hims premium tier at $499/month: $5,988/year (a $3,600 premium)
• For comparison: brand Wegovy at retail without insurance: $1,000-1,300/month, or $12,000-15,600/year

Hims is "expensive compared to compounded" but still much cheaper than retail. SkinnyRx is "cheap compared to brand" but still a $200/month subscription. The right framing depends on what you are comparing to.

Why SkinnyRx can charge less

Compounded semaglutide bypasses much of the cost stack of FDA-approved finished products:

• No FDA finished-product review and approval costs amortized into pricing
• No branded-manufacturer pricing power (Novo Nordisk, Eli Lilly)
• 503A compounding pharmacies operate on smaller margins than branded manufacturers
• Less marketing spend than nationally-televised brands

The trade-off you accept for the price reduction is the regulatory ambiguity around compounded products and, in SkinnyRx's specific case, the prior FDA warning on marketing language.

The Affirm financing factor

This is the underrated SkinnyRx differentiator. Many users can budget $50/week comfortably but cannot pay $199 in a single charge — and certainly not the $400-600 some providers charge for the first month (intake fee + first dose + shipping). SkinnyRx's Affirm integration breaks the subscription into smaller installments, removing the upfront-charge friction that causes many users to abandon checkout.

Hims does not currently offer Affirm financing for GLP-1 plans. Their pricing is what it is, paid monthly.

The FDA warning context: SkinnyRx, March 2026

This is the section where most affiliate-only sites would either skip the topic entirely or bury it in a footnote. We disclose it directly because honest disclosure of regulatory context is the only way reviews like this remain trustworthy.

What happened: in March 2026, the FDA issued warning letters to approximately 30 telehealth companies regarding promotional claims about compounded GLP-1 medications. The agency's concern was that certain marketing language — language used in ads, websites, and social posts — misbranded the products under the Federal Food, Drug, and Cosmetic Act. SkinnyRx was named among the recipients.

What it was not:

• Not a product recall
• Not a safety enforcement action
• Not an allegation that the active ingredient was contaminated, mislabeled, or substandard
• Not a shutdown order or cease-and-desist on the product

What SkinnyRx did:

• Revised the flagged marketing language
• Continued operating with no interruption to existing patient prescriptions
• Updated promotional copy across web and ad properties

How to weigh it:

• If you are uncomfortable with any provider that has had FDA enforcement attention of any kind, SkinnyRx is not the right choice for you. Hims & Hers, GobyMeds, or other clean-record providers are better fits.
• If you understand the warning was about marketing language and not the underlying product, and the $100-300/month savings outweigh that consideration for your situation, the warning is not disqualifying.
• Ask SkinnyRx (or any compounded provider) for a Certificate of Analysis from the compounding pharmacy. Reputable providers will share one on request.

Who should choose which

This is the practical question. Here is a clean decision framework.

Choose SkinnyRx if any of these apply

• Budget is the primary constraint. Saving $1,200-3,600 per year materially changes whether you can sustain treatment long-term, and treatment continuity matters more than which specific provider you pick.
• You need Affirm financing. If splitting the monthly bill is what makes treatment possible at all, SkinnyRx is one of the few legitimate compounded providers offering it.
• You want flexibility on formulation. Injectable, sublingual, and tablet options matter to users who specifically prefer not to inject.
• You understand and accept compounded regulatory caveats. The active ingredient is the same, the pharmacy is licensed, but the FDA has not approved the finished product. If that trade-off is acceptable in exchange for lower price, SkinnyRx is a legitimate choice.
• The March 2026 marketing-language warning is not disqualifying for you after reading the context above.

👉 Visit SkinnyRx → (affiliate link — see disclosure)

Choose Hims & Hers if any of these apply

• You want FDA-approved branded medications, period. No compounded ambiguity. If anything goes wrong, the regulatory chain (FDA → manufacturer → pharmacy → patient) is fully established.
• You want tirzepatide (Zepbound) specifically. The dual GLP-1 + GIP mechanism delivers ~22.5% mean weight loss in trials^[2] versus ~14.9% for semaglutide^[1]. If you want the more potent of the two, Hims is the path to FDA-approved tirzepatide.
• You will use insurance. Hims's branded products have a meaningful chance of coverage with prior authorization, particularly if your plan has weight loss benefits or you have qualifying comorbidities.
• You want 24/7 support. Hims's infrastructure delivers around-the-clock chat support, which matters during early titration weeks when questions and side effects come up at unpredictable hours.
• You are uncomfortable with any FDA warning history of any kind. Hims has no GLP-1-related warning letters; that is what you are paying the premium for.

👉 Visit Hims → (affiliate link — see disclosure)

A note both providers' fans miss

You are not stuck with the choice forever. People legitimately switch in either direction as their circumstances change — start on SkinnyRx during a budget-constrained year, move to Hims when employer coverage kicks in; or start on Hims during titration with full support, move to SkinnyRx for maintenance dosing once you know the medication agrees with you. There is no medical reason this sequencing has to be a one-way door, provided each transition is supervised by a licensed prescriber.

Honest cons of each provider

SkinnyRx — what to weigh against the lower price

• March 2026 FDA warning on marketing language. Disclosed above. Not disqualifying for many readers, disqualifying for some.
• Compounded products are not FDA-approved as finished products. Quality depends on the 503A pharmacy. SkinnyRx discloses theirs, which helps, but the FDA approval guarantee that comes with branded products is not present.
• Customer support is not 24/7. Business hours plus a ticket queue. Reasonable response times most of the time, slower during high-volume periods.
• Insurance coverage is unlikely. Compounded GLP-1 medications are almost never covered.
• Provider depth varies. Reputable telehealth platforms include legitimate licensed prescribers, but the time per consultation is generally shorter than a primary-care visit. If you have complex medical history, this can be a limitation.

Hims & Hers — what to weigh against the FDA-approved certainty

• Cost. $1,200-3,600/year more than SkinnyRx. For users on tight budgets, this can be the difference between starting and not starting treatment.
• No financing. Hims does not offer Affirm or comparable installment plans for GLP-1.
• Less formulation flexibility. FDA-approved injectable is the primary path, with the Wegovy oral pill as an alternative. No sublingual or compounded-tablet options.
• Wait times during peak demand. Hims is operationally large but not immune to backlogs during seasonal demand spikes (January, post-holiday).
• Less personalized than concierge providers. The scale that delivers 24/7 support also means provider continuity is lower than at smaller, dedicated weight-loss clinics.

What to expect on either path: side effects, titration, and stopping

Whichever provider you choose, the underlying medication behaves the same way. The STEP 1 trial^[1] data on semaglutide is the most relevant clinical reference for SkinnyRx, and STEP 1 plus SURMOUNT-1^[2] apply to Hims (Wegovy is FDA-approved semaglutide; Zepbound is FDA-approved tirzepatide).

Side effects (both products):

• Nausea: ~44% on semaglutide in early weeks, declining substantially by week 12
• Diarrhea, constipation, vomiting: dose-dependent
• Discontinuation due to GI events: ~4-5% in semaglutide trials; ~7% on tirzepatide at the 15 mg dose

Weight loss timeline (clinical trial averages):

• Week 4: ~3% body weight reduction
• Week 12: ~7-9%
• Week 24: ~12-14%
• Week 48: ~14.9% on semaglutide STEP 1^[1], ~22.5% on tirzepatide SURMOUNT-1^[2]

What happens when you stop: The STEP 4 trial^[4] showed that switching from semaglutide to placebo led to weight regain, and the broader extension data found that participants who stopped semaglutide regained roughly two-thirds of the weight they had lost over the following year. SURMOUNT-4^[3] showed the same pattern with tirzepatide. This frames the question of provider choice as a multi-year decision: you are picking a partner for ongoing treatment, not a one-time purchase.

Muscle preservation matters on either path

The Locatelli 2024 review^[5] emphasizes that resistance exercise during incretin-based weight loss therapy reduces lean-mass loss, which can otherwise account for 20-30% of the weight lost. Both SkinnyRx and Hims users should plan strength training into the protocol regardless of which provider they choose.

A few questions readers ask that don't fit the table

"Can I get tirzepatide from SkinnyRx?"

SkinnyRx's primary advertised product is compounded semaglutide. Some compounded telehealth providers also offer compounded tirzepatide; verify directly with SkinnyRx at intake what is currently offered. The compounded tirzepatide market shifted significantly after the FDA removed tirzepatide from the drug shortage list, which restricts when 503A pharmacies can compound it.

"Can I get the Wegovy oral pill from Hims?"

The Wegovy oral pill (FDA-approved tablet semaglutide) launched January 5, 2026. Hims has the relationships and infrastructure to offer this product to qualifying patients, with pricing typically in the $149-299/month range depending on dose. The strict morning-routine requirement (empty stomach, max 4 oz water, wait 30 minutes before food/drink/medication) is a real factor — if you cannot reliably hold that routine, the injectable is more effective.

"Which provider has better real-user reviews?"

Both have mixed reviews because both serve large user bases. Hims tends to score higher on operational reliability (shipping, customer service responsiveness) and lower on perceived value. SkinnyRx tends to score higher on pricing satisfaction and lower on customer-service speed during high-volume periods. Reddit and Trustpilot scans through April 2026 are consistent with this pattern. Individual experiences vary widely.

Bottom line

SkinnyRx and Hims & Hers are not direct competitors in the way the search results make them look. They are different products serving overlapping but distinct readers:

• SkinnyRx is the right answer if your priority is making GLP-1 treatment affordable and sustainable, you accept the regulatory profile of compounded medication, and the disclosed March 2026 marketing-language warning is something you have read and decided is acceptable.
• Hims & Hers is the right answer if your priority is FDA-approved branded certainty, you want access to tirzepatide (Zepbound) specifically, you have insurance worth pursuing prior authorization on, or you simply prefer the lowest-regulatory-risk path even at a $1,200-3,600/year premium.

This site is not in the business of pretending one of these is a "scam" so we can push you toward the other. Both have legitimate use cases. Pick the one that matches your priorities and constraints, then commit — treatment continuity over years matters far more than the marginal differences between two reputable providers.

Whatever you decide, talk to a licensed physician familiar with your medical history before starting, changing, or stopping a GLP-1 medication.

Frequently asked questions

Sources & clinical references

1. [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
3. [3] Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945
4. [4] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224
5. [5] Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. DOI: 10.2337/dci23-0100
6. [6] Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725
7. [7] Madsbad S, Holst JJ. The promise of GLP-1 RAs for obesity treatment. Expert Opin Investig Drugs. 2025. DOI: 10.1080/13543784.2025.2472408
8. [8] U.S. Food & Drug Administration warning letters to telehealth companies regarding compounded GLP-1 promotional claims, March 2026. (Public FDA warning-letter database.)

Disclaimers

FTC Affiliate Disclosure: This article contains affiliate links to SkinnyRx (current commission partner) and Hims & Hers (link marked sponsored; affiliate application pending). If you sign up through these links, we may receive commission at no additional cost to you. Editorial assessment is independent — we have given honest pros and cons of each provider rather than steering readers toward whichever currently pays us more. Both products have legitimate use cases for different reader needs.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, changing, or stopping any medication, including GLP-1 receptor agonists. Compounded medications carry regulatory and quality considerations beyond those of FDA-approved products — discuss with a physician familiar with your medical history. Information current as of May 4, 2026; verify pricing, FDA standing, and product availability directly with each provider before signup.